Gland Pharma Intrinsic Value
GLAND • Healthcare
Current Stock Price
₹1716.40
Primary Intrinsic Value
₹981.20
Market Cap
₹2918 Cr
+100.0%
Upside
Median Value
₹3432.80
Value Range
₹515 - ₹4291
Assessment
Trading Below Calculated Value
Safety Margin
50.0%
GLAND Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹981.20 | ₹784.96 - ₹1177.44 | -42.8% | EPS: ₹44.60, Sector P/E: 22x |
| Book Value Method | asset | ₹4291.00 | ₹3861.90 - ₹4720.10 | +150.0% | Book Value/Share: ₹5382.94, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹3432.80 | ₹3089.52 - ₹3776.08 | +100.0% | Revenue/Share: ₹3696.47, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹3432.80 | ₹3089.52 - ₹3776.08 | +100.0% | EBITDA: ₹1592.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹4291.00 | ₹3432.80 - ₹5149.20 | +150.0% | CF Growth: 10.9%, Discount: 15% |
| PEG Ratio Method | growth | ₹514.92 | ₹463.43 - ₹566.41 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹689.07 | ₹620.16 - ₹757.98 | -59.9% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹3432.80 | ₹3089.52 - ₹3776.08 | +100.0% | ROE: 8.0%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹2324.17 | ₹2091.75 - ₹2556.59 | +35.4% | EPS: ₹44.60, BVPS: ₹5382.94 |
Method Types:
Earnings
Asset
DCF
Growth
Dividend
Conservative
Valuation Comparison Chart
GLAND Intrinsic Value Analysis
What is the intrinsic value of GLAND?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Gland Pharma (GLAND) is ₹3432.80 (median value). With the current market price of ₹1716.40, this represents a +100.0% variance from our estimated fair value.
The valuation range spans from ₹514.92 to ₹4291.00, indicating ₹514.92 - ₹4291.00.
Is GLAND undervalued or overvalued?
Based on our multi-method analysis, Gland Pharma (GLAND) appears to be trading below calculated value by approximately 100.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 13.33 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 8.0% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 21.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.56x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Gland Pharma
Additional stock information and data for GLAND
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹915 Cr | ₹915 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹997 Cr | ₹123 Cr | Positive Free Cash Flow | 7/10 |
| March 2023 | ₹364 Cr | ₹364 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹791 Cr | ₹292 Cr | Positive Free Cash Flow | 7/10 |
| March 2021 | ₹605 Cr | ₹-155 Cr | Positive Operating Cash Flow | 6/10 |